Technological advances have profoundly affected people living with type 1 diabetes, their families or carers, and health-care systems. The innovations include the development of analogue insulins, continuous glucose monitoring (CGM) devices, applications that support carbohydrate counting and insulin dosing, insulin pumps, hybrid closed-loop therapy, and telemedicine. Multiple clinical trials1–3 and systematic reviews4,5 have demonstrated clinically relevant benefits of hybrid closed-loop therapy, but it is well established that trial participants and the intense clinical care scenario in which they participate within the trial might not be generalisable to the broader population of people with type 1 diabetes.

Technological advances have profoundly affected people living with type 1 diabetes, their families or carers, and health-care systems. The innovations include the development of analogue insulins, continuous glucose monitoring (CGM) devices, applications that support carbohydrate counting and insulin dosing, insulin pumps, hybrid closed-loop therapy, and telemedicine. Multiple clinical trials1–3 and systematic reviews4,5 have demonstrated clinically relevant benefits of hybrid closed-loop therapy, but it is well established that trial participants and the intense clinical care scenario in which they participate within the trial might not be generalisable to the broader population of people with type 1 diabetes.

Technological advances have profoundly affected people living with type 1 diabetes, their families or carers, and health-care systems. The innovations include the development of analogue insulins, continuous glucose monitoring (CGM) devices, applications that support carbohydrate counting and insulin dosing, insulin pumps, hybrid closed-loop therapy, and telemedicine. Multiple clinical trials1–3 and systematic reviews4,5 have demonstrated clinically relevant benefits of hybrid closed-loop therapy, but it is well established that trial participants and the intense clinical care scenario in which they participate within the trial might not be generalisable to the broader population of people with type 1 diabetes.

Technological advances have profoundly affected people living with type 1 diabetes, their families or carers, and health-care systems. The innovations include the development of analogue insulins, continuous glucose monitoring (CGM) devices, applications that support carbohydrate counting and insulin dosing, insulin pumps, hybrid closed-loop therapy, and telemedicine. Multiple clinical trials1–3 and systematic reviews4,5 have demonstrated clinically relevant benefits of hybrid closed-loop therapy, but it is well established that trial participants and the intense clinical care scenario in which they participate within the trial might not be generalisable to the broader population of people with type 1 diabetes.

Using prevalence data from the UK,1 we estimate that there are more than 10 000 university students with type 1 diabetes, out of a total student population of 2·8 million.